Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to KCNA3" (ENSG00000300042) is a non-coding RNA transcript identified in genome annotations as being transcribed from the DNA strand opposite to the KCNA3 gene, whose product is the potassium voltage-gated channel subfamily A member 3. As an antisense RNA, its main characteristic is its genomic position rather than any established biological or pharmacological function. There is no evidence that this transcript produces a functional protein, or that it has been implicated as a direct therapeutic target, disease biomarker, or in any clinical context[6]. Summary of issues: This entry does not meet the criteria for a canonical therapeutic target, and information on biological relevance, function, or druggability is lacking. If your interest is KCNA3, refer to "Potassium voltage-gated channel subfamily A member 3" (KCNA3), which is a well-characterized ion channel with significant biological and clinical relevance[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to KCNA3.